Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer

(2023) Mayur M. Amonkar et al.   Cancer Treatment and Research Communications

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

(2023) Angela DeMichele et al.   Targeted Oncology

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

(2022) L. Paz-Ares et al.   ESMO Open

Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans

(2022) Ibrahim Azar et al.   JAMA Network Open

Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).

(2021) Eric S. Nadler et al.   JOURNAL OF CLINICAL ONCOLOGY

P63.05 Treatment Pattern in Small Cell Lung Cancer: A Real-world Observational Study in the Era of Immune Checkpoint Inhibitors

(2021) K. Zu et al.   Journal of Thoracic Oncology

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors

(2020) Eric Nadler et al.   ADVANCES IN THERAPY

Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials

(2020) D.E. Magee et al.   ANNALS OF ONCOLOGY

Treatment patterns in extensive-stage small cell lung cancer: A retrospective real-world data study.

(2020) Apar Kishor Ganti et al.   JOURNAL OF CLINICAL ONCOLOGY

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

(2020) Bassel Nazha et al.   Future Oncology

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study

(2020) Eric Nadler et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review

(2019) A. Sun et al.   Current Oncology

Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer

(2019) Weilin Meng et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Managing Patients With Relapsed Small-Cell Lung Cancer

(2018) Jun Gong et al.   Journal of Oncology Practice

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment advances in small cell lung cancer (SCLC)

(2017) Saiama N. Waqar et al.   PHARMACOLOGY & THERAPEUTICS

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY